← Back to All US Stocks

LFVN Stock Analysis 2026 - Lifevantage Corp AI Rating

LFVN Nasdaq Pharmaceutical Preparations CIK: 0000849146
Recently Updated • Analysis: Apr 12, 2026 • SEC Data: 2025-12-31
SELL
68% Conf
Pending
Analysis scheduled

📊 LFVN Key Takeaways

Revenue: $96.5M
Net Margin: 2.5%
Free Cash Flow: $-1.0M
Current Ratio: 2.03x
Debt/Equity: 0.00x
EPS: $0.19
AI Rating: SELL with 68% confidence

Is LFVN a Good Investment? Thesis Analysis

Claude

Lifevantage demonstrates revenue growth and improved net income, but exhibits severe cash generation weakness with negative free cash flow (-$1.0M) despite profitability, indicating earnings quality concerns. Extremely thin operating margins (2.9%) and operating cash flow conversion of only 0.5% of revenue create sustainability risks.

Why Buy LFVN? Key Strengths

Claude
  • + Strong gross margins at 76.7% demonstrate pricing power and cost efficiency
  • + Zero long-term debt and debt-to-equity ratio of 0.00x provide robust financial flexibility
  • + Revenue growth of 14.2% year-over-year shows market demand and top-line momentum

LFVN Investment Risks to Consider

Claude
  • ! Negative free cash flow of -$1.0M despite positive net income signals earnings quality issues and potential unsustainable profitability
  • ! Operating cash flow of only $486K represents just 0.5% of $96.5M revenue, indicating poor cash conversion
  • ! Razor-thin operating margin of 2.9% and net margin of 2.5% leave no margin for error in execution or market conditions

Key Metrics to Watch

Claude
  • * Operating cash flow trend and cash conversion ratio - must demonstrate positive trend to validate profitability
  • * Free cash flow sustainability and working capital management efficiency
  • * Operating margin expansion capability - growth must translate to margin improvement

LFVN Financial Metrics

Revenue
$96.5M
Net Income
$2.4M
EPS (Diluted)
$0.19
Free Cash Flow
$-1.0M
Total Assets
$61.2M
Cash Position
$10.2M

💡 AI Analyst Insight

Strong liquidity with a 2.03x current ratio provides a solid financial cushion.

LFVN Profitability Ratios

Gross Margin 76.7%
Operating Margin 2.9%
Net Margin 2.5%
ROE 7.4%
ROA 4.0%
FCF Margin -1.1%

LFVN vs Healthcare Sector

How Lifevantage Corp compares to Healthcare sector averages

Net Margin
LFVN 2.5%
vs
Sector Avg 12.0%
LFVN Sector
ROE
LFVN 7.4%
vs
Sector Avg 15.0%
LFVN Sector
Current Ratio
LFVN 2.0x
vs
Sector Avg 2.0x
LFVN Sector
Debt/Equity
LFVN 0.0x
vs
Sector Avg 0.6x
LFVN Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is LFVN Overvalued or Undervalued?

Based on fundamental analysis, Lifevantage Corp has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
7.4%
Sector avg: 15%
Net Profit Margin
2.5%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

LFVN Balance Sheet & Liquidity

Current Ratio
2.03x
Quick Ratio
1.03x
Debt/Equity
0.00x
Debt/Assets
46.1%
Interest Coverage
N/A
Long-term Debt
$0.0

LFVN 5-Year Financial Trend & Growth Analysis

LFVN 5-year financial data: Year 2021: Revenue $232.9M, Net Income $7.4M, EPS $0.50. Year 2022: Revenue $232.9M, Net Income $11.5M, EPS $0.79. Year 2023: Revenue $213.4M, Net Income $3.1M, EPS $0.24. Year 2024: Revenue $213.4M, Net Income $2.5M, EPS $0.20. Year 2025: Revenue $228.5M, Net Income $2.9M, EPS $0.23.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Lifevantage Corp's revenue has remained relatively flat over the 5-year period, with a 2% decline. The most recent EPS of $0.23 reflects profitable operations.

LFVN Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-1.1%
Free cash flow / Revenue

LFVN Quarterly Performance

Quarterly financial performance data for Lifevantage Corp including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q2 2026 $48.9M $276.0K $0.02
Q1 2026 $47.2M $1.8M $0.14
Q3 2025 $48.2M $629.0K $0.13
Q2 2025 $51.6M -$27.0K $0.00
Q1 2025 $47.2M $629.0K $0.05
Q3 2024 $48.2M $574.0K $0.05
Q2 2024 $51.6M -$27.0K $0.00
Q1 2024 $51.4M $610.0K $0.05

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

LFVN Capital Allocation

Operating Cash Flow
$486.0K
Cash generated from operations
Stock Buybacks
$577.0K
Shares repurchased (TTM)
Capital Expenditures
$1.5M
Investment in assets
Dividends Paid
$1.1M
Returned to shareholders

LFVN SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for Lifevantage Corp (CIK: 0000849146)

📋 Recent SEC Filings

Date Form Document Action
Apr 3, 2026 4 xslF345X06/ownership.xml View →
Apr 3, 2026 4 xslF345X06/ownership.xml View →
Apr 3, 2026 4 xslF345X06/ownership.xml View →
Apr 3, 2026 4 xslF345X06/ownership.xml View →
Mar 18, 2026 4 xslF345X06/ownership.xml View →

Frequently Asked Questions about LFVN

What is the AI rating for LFVN?

Lifevantage Corp (LFVN) has an AI rating of SELL with 68% confidence, based on fundamental analysis of SEC EDGAR filings.

What are LFVN's key strengths?

Claude: Strong gross margins at 76.7% demonstrate pricing power and cost efficiency. Zero long-term debt and debt-to-equity ratio of 0.00x provide robust financial flexibility.

What are the risks of investing in LFVN?

Claude: Negative free cash flow of -$1.0M despite positive net income signals earnings quality issues and potential unsustainable profitability. Operating cash flow of only $486K represents just 0.5% of $96.5M revenue, indicating poor cash conversion.

What is LFVN's revenue and growth?

Lifevantage Corp reported revenue of $96.5M.

Does LFVN pay dividends?

Lifevantage Corp pays dividends, with $1.1M distributed to shareholders in the trailing twelve months.

Where can I find LFVN SEC filings?

Official SEC filings for Lifevantage Corp (CIK: 0000849146) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is LFVN's EPS?

Lifevantage Corp has a diluted EPS of $0.19.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is LFVN a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Lifevantage Corp has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is LFVN stock overvalued or undervalued?

Valuation metrics for LFVN: ROE of 7.4% (sector avg: 15%), net margin of 2.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy LFVN stock in 2026?

Our dual AI analysis gives Lifevantage Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is LFVN's free cash flow?

Lifevantage Corp's operating cash flow is $486.0K, with capital expenditures of $1.5M. FCF margin is -1.1%.

How does LFVN compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin 2.5% (avg: 12%), ROE 7.4% (avg: 15%), current ratio 2.03 (avg: 2).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 12, 2026 | Data as of: 2025-12-31 | Powered by Claude AI